The FDA cleared marketing for the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.

The U.S. Food and Drug Administration cleared the first in vitro diagnostic device that tests blood to aid in diagnosing ...

Dr. Richard G. Stefanacci explains why the FDA's recent clearance of a diagnostic blood test for Alzheimer's deserves ...

The FDA has approved the first blood test to detect signs of Alzheimer’s disease, marking a major step toward easier diagnosis. The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test ...

Joe Walsh is the first Alzheimer's patient to be treated with an experimental nasal spray designed to reduce inflammation in ...

old, who were clinically normal and cognitively unimpaired at baseline after an extensive battery of neurocognitive assessments, tested positive for amyloid-beta protein after a PET scan. Since the ...

This ratio is correlated to the presence or absence of amyloid plaques in the brain, reducing the need for a PET scan. In 2022, the FDA approved the Lumipulse G Beta-Amyloid Ratio (1-42/1-40 ...

To investigate, Shekhtman and colleagues surveyed 199 at-risk, but cognitively normal, adults before and 6 months after they underwent amyloid PET scans to determine amyloid beta status.

The blood test measures two subtypes of tau and amyloid proteins, which can indicate the presence of amyloid plaque in the ...

correlated to amyloid plaque) Advanced Positron Emission Tomography (PET) scan imaging, using the Positrigo NeuroLF brain PET system recently cleared by the U.S. FDA, to confirm amyloid plaque ...